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Bronchodilators are the mainstay of COPD treatment and can be combined with
inhaled corticosteroids for greater efficacy and fewer side effects. A new generation
of pharmacotherapeutic agents, most notably phosphodiesterase-4 inhibitors, which
are already in the advanced stages of clinical development, and leukotriene B4
inhibitors (in early clinical development), may shape future treatment as further
insight is gained into the pathological mechanisms underlying COPD.
Non-pharmacologic treatments for COPD include long-term oxygen therapy
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Treatments for COPD S29only treatment to date which has been shown to modify survival rates in severe
cases; thus its role in COPD is well defined. The roles of nPPV and LVRS are less clear,
though recent progress is reported here.
In the future, it will be important to establish the precise value of the different
treatments available for COPD—evaluating both clinical and physiological endpoints
and using the data to more accurately define candidate patients accordingly. The
challenge will be to develop this base of knowledge in order to shape future research
and allow clinicians to deliver tailored COPD management programmes for the
growing number of patients afflicted with this disease.
& 2005 Elsevier Ltd. All rights reserved.Introduction
Chronic obstructive pulmonary disease (COPD) is a
multicomponent disease with inflammation at its
core, in which patients experience progressively
worsening lung function, disease symptoms and
quality of life (QoL), as well as increasing exacer-
bations.1 The therapeutic difficulty presented by
COPD arises from the need to target all components
of the disease. To this end, a clinician’s paradigm
for COPD management has been introduced—
Global Initiative for Chronic Obstructive Lung
Disease 2003 (GOLD 2003).1,2 Current management
options can be divided into pharmacologic and non-
pharmacologic categories. Pharmacologic treat-
ments include bronchodilators, inhaled corticoster-
oids (ICS), combination therapies and long-term
oxygen therapy (LTOT). Non-pharmacologic inter-
ventions include smoking cessation, optimising
nutrition, pulmonary rehabilitation, mechanical
ventilation and lung-volume-reduction surgery
(LVRS). Novel medications such as selective phos-
phodiesterase-4 (PDE4) inhibitors are already in the
advanced stages of clinical development; leuko-
triene B4 (LTB4) inhibitors also show potential for
shaping future therapy, although they are only in
the early stages of clinical development. Apart
from smoking cessation, LTOT is the only treatment
to date that has been shown to modify survival
rates in severe COPD; thus it has a clear role to play
in patients with COPD and chronic respiratory
failure. The aim of this article is to provide an
overview of the current and future treatment
options available in COPD management.Pharmacotherapeutic agents in COPD
Bronchodilators
Optimising treatment response
Bronchodilators are central to the symptomatic
management of COPD and come in several for-
ms—short-acting bronchodilators, including the b2-agonist salbutamol and the anticholinergic ipratro-
pium bromide, and long-acting bronchodilators,
including the b2-agonists salmeterol and formoter-
ol, the anticholinergic tiotropium and theophylline.
A fixed-dose combination of salbutamol/ipratro-
pium (Combivents) is also available.
Current guidelines recommend the inhaled de-
livery of long-acting bronchodilators as the pre-
ferred method of therapy. Several facts should be
considered when choosing a bronchodilator for
treatment of COPD. First, the lack of acute
response to one class of bronchodilator does not
necessarily imply non-responsiveness to another.
Donohue3 reported that 73% of 813 COPD patients
increased their forced expiratory volume in 1 s
(FEV1) by 412% or 200mL following long-term
salmeterol treatment. However, 11% of patients
showed a similar increase in FEV1 following acute
administration of ipratropium, 27% following salbu-
tamol and 35% with both drugs combined. A second
consideration is that a patient’s FEV1 response to
acute bronchodilator therapy does not predict
long-term response to bronchodilator therapy and
may vary from day to day. Calverley et al.4
performed acute bronchodilator testing using sal-
butamol, ipratropium bromide or a combination of
the two on 660 COPD patients who had been
classified according to both European Respiratory
Society (ERS) and American Thoracic Society (ATS)
spirometric criteria.5,6 Over the 2-month study
period, 55% of patients classified as irreversible
under ATS criteria changed to reversible status on
at least one of the visits.
In summary, the acute response to short-acting
bronchodilators is of limited value in deciding
future response to long-acting agents. Further-
more, while improvement in FEV1 is important in
assessing response to bronchodilator therapy, other
outcome measures such as improvements in lung
volumes, symptoms, exercise capacity, QoL and
exacerbations may be of greater value in assessing
the long-term response. The effects of commonly
used bronchodilators on clinical outcomes in COPD
are listed in Table 1.
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Table 1 Summary of the effects of commonly used bronchodilators on clinical outcomes in COPD.
Bronchodilator FEV1 Lung volume Dyspnoea HRQoL Exercise endurance
Short-acting b-agonist Yes Yesy Yes — Yesy
Ipratropium bromide Yes Yesy Yes Noy Yesy
Long-acting b-agonist Yes Yes Yes Yes Yesy
Tiotropium Yes Yes Yes Yes Yesy
Theophylline Yes Yesy Yes Yesy Yesy
FEV1 ¼ forced expiratory volume in 1 s.
Randomised clinical trial, substantial numbers of studies with large study populations.
yRandomised clinical trial, few studies or studies with small study populations.
N.A. Hanania et al.S30Combination bronchodilator therapy
Current guidelines highlight the fact that a combi-
nation of more than one class of bronchodilator
may be more effective than the use of single agents
with respect to improvements in lung function,
symptoms, and reducing the risk of adverse
events.1 This has been supported by several clinical
trials. For example, in a 12-week trial, ZuWallack
et al.7 showed that salmeterol plus theophylline
caused significantly greater improvements in pul-
monary function and symptoms, compared with
either single agent (N ¼ 943). Additionally, the
combination of salmeterol and the short-acting
anticholinergic ipratropium provided greater
bronchodilation than either agent alone.8 These
additive effects are not surprising since these
agents may have complementary mechanisms of
action.9Assessing bronchodilator efficacy
FEV1 is not the only useful physiological endpoint in
evaluating bronchodilator efficacy—changes in
symptoms and QoL often occur independently of
changes in lung function. Other important physio-
logical effects of bronchodilators include the
reduction of air trapping and dynamic hyperinfla-
tion. Assessments of bronchodilator efficacy should
take these factors into consideration. For example,
the degree of lung hyperinflation, determined using
lung volume measurements of inspiratory capacity,
may provide a better correlation than FEV1, with
improved exercise performance following broncho-
dilator therapy.10 Clinical endpoints, such as the
frequency of exacerbations, mortality, degree of
breathlessness, exercise tolerance and health
status should equally be incorporated.11,12
It should also be noted that some bronchodilators
exhibit beneficial non-bronchodilator behaviour,
such as the potential anti-inflammatory effects of
theophylline13 and other non-bronchodilatory ef-
fects of long-acting b2-agonists (LABA).
14Safety of bronchodilators
It has been reported that the continued use of b2-
agonists may be associated with an increase in
cardiovascular risk compared with placebo.15 How-
ever, a recent meta-analysis (N ¼ 2853) showed no
clinically significant difference in the incidence of
cardiovascular events between salmeterol and
placebo.16 Furthermore, a study in patients with
cardiovascular disease showed no increased risk
with the use of salmeterol, compared with place-
bo.17 It has also been suggested that tolerance to
the bronchodilator effects of LABAs may occur with
their prolonged use. A recent study examining the
bronchodilator effect of long-term use of salmeter-
ol failed to demonstrate such an effect.18
The use of anticholinergics may be associated
with class side effects, such as dry mouth, an
increased risk of glaucoma and urinary retention.
Long-term effects of ipratropium bromide may
include an increased risk of cardiac events, as
shown in the Lung Health Study, although these
findings need further evaluation.19 Theophylline is
associated with tremors and nausea and less
frequently, with cardiac arrhythmias and sei-
zures.20 The risk of such adverse events can be
reduced, however, by monitoring drug plasma
levels and reducing the dose accordingly.Future challenges in bronchodilator therapy
Several new bronchodilators, currently in ongoing
clinical trials, may improve the future treatment of
COPD. These include b2-agonists, which can be
administered once a day or through nebulisation,
PDE4 inhibitors and combination therapies. Specific
research targets include determining the long-term
efficacy of ICS/LABA combinations and tiotropium,
their effects on the natural history of COPD when
used early in disease progression, and their long-
term safety. The exploration of more reliable and
sensitive markers for response to bronchodilator
therapy is also a key objective.
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The role of ICS in COPD was once controversial, but
is now better established as a result of large clinical
trials. Regular treatment with ICS is recommended
(GOLD) for symptomatic patients who suffer fre-
quent exacerbations, and whose FEV1 is o50% of
predicted.1 The rationale for the use of ICS in COPD
will be examined below.
Attempts to elucidate the ICS mechanism of
action have been inconclusive. Although these
agents appear to have minimal significant effects
on key inflammatory chemoattractants, such as
interleukin-8 (IL-8), tumour necrosis factor-alpha
(TNF-a) and matrix metalloproteinases,21 there are
data to suggest an association with reduced
neutrophil chemotaxis.22Figure 1 The effects of ICS/LABA combination therapy
on (A) the number of exacerbations requiring oral steroid
courses (FEV1o50% predicted),36 and (B) QoL in patients
with COPD, as measured with the St. George’s Respira-
tory Questionnaire (SGRQ).32,33ICS in COPD: physiological versus clinical
endpoints
Four large, 3-year, randomised trials have failed to
show a significant effect of ICS on the rate of
decline of FEV1, compared with placebo.
23 How-
ever, a meta-analysis by Sutherland et al.24 showed
that high-dose ICS reduced the rate of decline in
FEV1 by 9.9mL per year compared with placebo
(P ¼ 0:01). Whether this effect is clinically impor-
tant remains unresolved. Less contentious data
showed that post-bronchodilator FEV1 was signifi-
cantly higher during ICS treatment compared with
placebo in two long-term studies,25,26 with parti-
cularly strong data in one study of fluticasone
propionate.25
Despite the controversy regarding the effects of
ICS on physiological endpoints, it is generally
agreed that ICS have a positive influence on clinical
endpoints in patients with COPD. For example, in
the Inhaled Steroids in Obstructive Lung Disease in
Europe trial, the median exacerbation rate was
reduced by 25% with fluticasone propionate com-
pared with placebo, with a concomitant significant
reduction in health status deterioration.25,27
Furthermore, these effects may be more pro-
nounced in patients with severe airflow limit-
ation—although the recent ATS/ERS statement
put as much emphasis on symptoms to guide
management decisions as lung function.2 It is
important to note that the COPE study also showed
that withdrawal from treatment with ICS was
associated with a more rapid onset and increased
recurrence of exacerbations, and also with a
significant deterioration in health-related quality
of life (HRQoL).28 Despite the contention surround-
ing the physiological effects of ICS, their effect on
clinical endpoints supports their use in COPD.Combining ICS and LABA for greater effectiveness
Physiological and clinical data concur that combin-
ing ICS and LABA is more effective than either
treatment alone.29–33 More recently, it has been
shown that short-term treatment with combined
fluticasone propionate/salmeterol improves lung
function and symptoms more effectively than the
combination of salbutamol and ipratropium bro-
mide.34,35 In a pivotal study, Calverley et al.29
(N ¼ 1465) reported that treatment for 12 months
with salmeterol/fluticasone propionate combina-
tion (SFC) significantly improved pre-treatment
FEV1 compared with placebo or either single agent
alone. A clinically significant improvement in
health status and a reduction in daily symptoms
were also observed with combination treatment,
together with a significant reduction in exacerba-
tions (Fig. 1).36 Other studies by Szafranski 32 and
Calverley33 showed that patients treated with a
budesonide/formoterol combination have an im-
proved QoL, as measured by the St George’s
Respiratory Questionnaire (SGRQ) score (Fig.
1).32,33,37 Furthermore, a database study by Soriano
et al.38 indicated that there may be a survival
advantage in using SFC combination treatment
or fluticasone propionate alone—the 3-year TO-
wards a Revolution in COPD Health survival study
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hypothesis further.39
In summary, ICS may have limitations as mono-
therapy in COPD. However, they have been shown
to significantly improve important clinical out-
comes in combination with LABAs, thus maintaining
the rationale for their use among these patients.
The next generation of pharmacotherapeutic
agents
Further insight into the pathogenesis of the chronic
airway inflammation which underlies COPD has
established new therapeutic targets, most of which
are based on components of inflammatory path-
ways (Fig. 2).40,41
PDE4 inhibitors
PDE4 is commonly expressed in neutrophils, CD8+
cells and macrophages. The inhibition of PDE4
causes an increase in cyclic adenosine monopho-
sphate in immunomodulatory and inflammatory
cells, with subsequent suppression of inflammatory
cell function. A number of PDE4 inhibitors are
undergoing investigation (Fig. 3). Selective PDE4
inhibitors,42 such as cilomilast and roflumilast, are
effective in COPD patients (Fig. 3). In particular,
cilomilast treatment is associated with reductions
in the numbers of CD8+ and CD68+ cells, indicating
anti-inflammatory action.43 The development ofFigure 2 Components of inflammatory pathways witPDE4 inhibitors is restricted by gastrointestinal side
effects, although this problem could be overcome
by the use of PDE4B-selective inhibitors, which may
be more specific and exert fewer side effects.44
LTB4 inhibitors
Another inflammatory mediator, LTB4, is a key
chemoattractant of neutrophils, thereby making it
an attractive target for therapeutic intervention in
COPD. Antagonists of the two subtypes of LTB4
receptor (e.g. LY2931144 and SB20114645) are at the
early stages of clinical development and have been
shown to inhibit sputum-induced neutrophil che-
motaxis (Fig. 4). Alternatively, inhibitors of LTB4
synthesis (e.g. BAYx1005) produce a modest reduc-
tion in sputum LTB4 concentrations,
46 although the
clinical relevance of this result is still to be
established.
Inhibiting cytokines and chemokines
There are a number of chemokines and cytokines
that play important roles in mediating inflamma-
tion in COPD, and are therefore potential ther-
apeutic targets. For example, IL-8 recruits and
activates neutrophils via the chemokine receptors
CXCR1 and CXCR2, and it can be inhibited by the
small-molecule CXCR1/CXCR2 antagonist, reper-
taxin.47 In addition, CXCR2-specific antagonists,
such as SB 225002, block the CXCR2 receptor which
is required for the recruitment of neutrophils.44h potential as therapeutic targets in COPD.40,41
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Figure 3 The next generation of phosphodiesterase-4 inhibitors.42
Figure 4 Effect of a leukotriene B4 (LTB4) receptor
antagonist, SB 201146, on sputum-induced neutrophil
chemotaxis.46
Treatments for COPD S33An alternative means of intercepting the IL-8
pathway is to use a human anti-IL-8 monoclonal
antibody. However, chemokine pathways exhibit a
degree of redundancy, so inhibiting any one
element may not be effective. Thus Beeh et al.45
investigated the effect of combining an anti-IL-8
antibody with an LTB4 antagonist, and found that
the combined effect was not significantly greater
than the effect of either single agent alone.
A further addition to the list of therapeutic
targets is TNF-a, which induces IL-8 via nuclear
factor-kappa B (NF-kB). The use of humanised
monoclonal antibodies (infliximab) and soluble
TNF-a receptors (etanercept) is currently being
investigated.44 In addition, the direct inhibition of
NF-kB is another means of intercepting the cyto-
kines and chemokines involved in COPD. The p38
mitogen-associated protein kinase pathway, which
also regulates the expression of inflammatory
cytokines, is a further potential target for the
development of small-molecular inhibitors, such as
SB 239063, which has demonstrated anti-inflamma-
tory activity in animal models.48
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Central to the pathogenesis of COPD, and in
addition to inflammation, is the imbalance in the
lung between endogenous proteinases and antipro-
teinases, and the production of oxidative stress.
The use of N-acetylcysteine (NAC), to provide
intracellular cysteine for the production of the
endogenous antioxidant, glutathione, is one of
several treatment options under investigation.
Initial research suggests that oral NAC reduces
the number of exacerbations in COPD49,50 but a
more recent randomised controlled trial failed
to show that the addition of NAC, to treat-
ment with corticosteroids and bronchodilators,
can modify the outcome in acute exacerbations
of COPD.51
In terms of restoring the balance between
proteases and protease inhibitors in COPD, the
development of small-molecular inhibitors of pro-
teinases, especially those which show elastolytic
activity, is a promising area.Long-term oxygen therapy (LTOT)
Rationale
Supplemental oxygen therapy is the only existing
approach shown to modify the long-term decline in
lung function that is associated with COPD—no
pharmacological treatment has so far demon-
strated this ability. LTOT has also been associated
with a variety of other benefits in patients with
severe COPD, including increased survival,52 re-
duced secondary polycythaemia, improved cardiac
function during rest and exercise,53 reduction in
the oxygen cost of ventilation54 and improved
exercise tolerance.55 Of particular note are the
results of a longitudinal study showing that LTOT
significantly improved HRQoL at 2 and 6 months,
compared with a progressive decline in HRQoL in
the non-LTOT group. In the LTOT group, 67% and
68% of patients (at 2 and 6 months, respectively)
showed a clinically significant improvement in their
chronic respiratory questionnaire scores.49 Hence
there is a convincing rationale for including LTOT
in the treatment paradigm for patients with
severe COPD.
Candidate patients for LTOT
Patients with PaO2o7.3 kPa (55mmHg; correspond-
ing to SaO2o88%) whose disease is stable despite
receiving otherwise comprehensive medical treat-
ment, should receive LTOT. A patient whose PaO2 is7.3–7.8 kPa (55–59mmHg; SaO2 89%) should receive
LTOT if they show signs of pulmonary hyper-
tension, cor pulmonale, erythrocytosis, oedema
from right heart failure or impaired mental state.
If oxygen desaturation only occurs during exercise
or sleep, then oxygen therapy should be con-
sidered specifically under those conditions. An
optimal medical regimen can be established in-
corporating these guidelines (Fig. 5),2 with the
chief aim of achieving optimised ventilation:perfu-
sion ratio matching (V 0=Q ) as a means of correcting
hypoxaemia.Oxygen therapy during sleep
COPD patients undergo episodes of O2 desaturation
of arterial blood during rapid eye movement sleep.
Fletcher et al.56 revealed that these desaturations
occur both in non-hypoxaemic patients, and in
patients who are hypoxaemic during the day.
Further research by Plywaczewski et al.57 showed
that 47.6% of COPD patients treated with LTOT
spent430% of the night with an SaO2 ofo90%, and
thus required increased oxygen flow during sleep.
The administration of oxygen at a flow rate higher
than the daytime setting usually corrects nocturnal
hypoxaemia.
Conflicting evidence surrounds the contention
that patients who only desaturate during sleep
will benefit from nocturnal oxygen treatment.
Kimura et al. reported increased mortality among
patients with nocturnal desaturation and daytime
PaO2X8 kPa (60mmHg).
58 But while Fletcher
et al.56 found a beneficial effect of supplemental
oxygen treatment in this patient group, other well-
controlled studies have not shown that the use of
nocturnal supplemental oxygen alters mortality or
clinical course, other than slightly lowering pul-
monary artery pressure.59Oxygen therapy during exercise
Oxygen therapy during exercise decreases dys-
pnoea and improves exercise tolerance at submax-
imal exertion. The mechanical rationale underly-
ing this observation is a decrease in dynamic
hyperinflation, and reduced ventilatory drive.55
LTOT is prescribed for patients who become more
hypoxaemic during exercise, or who only become
hypoxaemic during exercise, with oxygen settings
determined while the patient is undergoing a
typical level of exertion. Studies evaluating the
long-term benefit of oxygen treatment solely for
exercise have yet to be conducted.
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Figure 5 Algorithm for long-term oxygen therapy (LTOT).2
Treatments for COPD S35LTOT: cause for concern?
Carbon dioxide retention
Although LTOT may lead to hypercapnia with
resulting respiratory acidosis,60 this can usually be
minimised by titrating the oxygen flow to maintain
the PaO2 at 8.0–8.6 kPa (60–65mmHg). In fact,
many patients with COPD have chronic CO2 reten-
tion but because they have intact renal systems,
they are able to maintain their pH within the
normal range.Patient education and compliance
A more immediate obstacle for successful LTOT
administration is patient compliance. The mean
number of oxygen breathing hours actually com-
pleted by patients may be fewer than prescribed,
perhaps due to deficiencies in the practical
implementation or understanding of the condition.
Social barriers and psychological fears also play an
important role. Increasing patient education is
therefore a key challenge for the future. Interna-
tional agreement on the prescription of LTOT,selecting appropriate candidates and individualis-
ing oxygen prescriptions should establish clear
understanding of treatment by both patients and
clinicians.Noninvasive ventilation
Introducing nasal positive pressure
ventilation (nPPV)
Mechanical ventilation increases or substitutes for
an individual’s spontaneous respiration, as in the
case of acute respiratory or ventilatory pump
failure. Non-invasive ventilation, for example,
intermittent negative pressure ventilation (INPV)
or nPPV, have recently re-emerged as popular
options that avoid the risks associated with invasive
ventilation. nPPV is thought to assist ventilation, by
improving inspiratory flow rate and correcting
hypoventilation. Other possible mechanisms of
action include resting respiratory muscles and
resetting the central respiratory drive. In the
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tion in stable, chronically hypercapnic COPD
patients will be examined.Physiological endpoints revisited
In contrast to the evidence supporting the use of
nPPV to tackle other causes of chronic respiratory
failure, there is conflicting evidence regarding the
benefits of nPPV in COPD.61 Ambrosino et al.62
presented evidence that nPPV corrects hypoventi-
lation in patients with severe stable COPD and
chronic hypercapnia (n ¼ 8). In a study by Meec-
ham-Jones et al.,63 nocturnal and daytime gas
exchange, total sleep time and QoL significantly
improved with oxygen plus nPPV, compared with
oxygen alone. Indeed, the level of improvement in
daytime PaCO2 correlated with the level of im-
provement in mean overnight PaCO2 (R ¼ 0:69,
P ¼ 0:01). Taken together, these studies provide
support for the idea that non-invasive ventilation,
and nPPV in particular, may be a useful addition to
the treatment armoury for chronic hypercapnic
COPD.Randomised trials: conflicting results
Do randomised clinical trials of non-invasive venti-
lation support the use of this treatment modality?
Results for INPV are unconvincing. In a 12-week
double-blind study of 184 patients with severe
COPD, no significant difference was observed in 6-
min walk test results, cycle endurance time,
severity of dyspnoea, HRQoL, respiratory muscle
strength or arterial blood gas compared with sham
treatment.64 This suggests that inspiratory muscle
rest has no benefits for patients with severe stable
COPD, although poor patient compliance may have
contributed to the results.
Regarding the administration of nPPV in patients
with severe COPD, two 3-month crossover trials of
similar design came to different conclusions.
Strumpf et al.65 found no improvement in physio-
logical outcomes (N ¼ 19). In contrast to this result
is the study by Meecham-Jones et al.63 mentioned
in the previous section, in which nocturnal and
daytime gas exchange, total sleep time and QoL
significantly improved with oxygen plus nPPV
(N ¼ 18). The discrepancy between these results
may be explained by the difference between
patient sets at baseline: patients with greater CO2
retention and more frequent nocturnal oxygen
desaturations may benefit more from nPPV admin-
istration.Unfortunately, this neat solution is not supported
by subsequent trials. Despite efforts to recruit
hypercapnic patients with severe COPD, Gay et
al.66 found no significant improvements in gas
exchange, lung function or sleep quality compared
with the sham group. A recent 1-year study was
unable to demonstrate a beneficial effect of
nocturnal nPPV in addition to LTOT in a similar
patient group.67
In addition to these conflicting data on physiolo-
gical endpoints is a lack of data showing whether
nPPV treatment actually improves survival rates.
Therefore, it appears that larger studies with
greater statistical power are required, along with
follow-up data on morbidity and mortality.
nPPV in COPD—bigger trials, better results?
Two large, multicentre trials have focused on nPPV
in patients with severe hypercapnic COPD. One trial
published as an abstract by Muir et al., which
compared home nPPV plus LTOT with LTOT alone,
indicates that there is no overall survival benefit in
patients receiving nPPV plus LTOT, although there
may be a slight improvement in survival for patients
over 65.68 A 2-year Italian multicentre study also
examined the effects of nPPV plus LTOT compared
with LTOT alone (N ¼ 122). In this trial, nPPV plus
LTOT improved PaCO2 during breathing of the usual
oxygen inspiratory fraction. Long-term improve-
ments were also noted in dyspnoea and HRQoL in
the nPPV plus LTOT group, but survival was similar
between treatment groups.69
Currently, there is little evidence for the use of
mechanical ventilatory support in the routine
management of COPD. However, further large
studies may be able to identify subsets of patients
for whom nPPV would be beneficial.LVRS for emphysema
Current understanding of LVRS
LVRS was originally proposed as a palliative treat-
ment for patients with severe emphysema. The
rationale for LVRS is based on the premise that
these patients have severe hyperinflation and the
goal of surgery is to remove functionally useless
emphysematous lung. Generally, this involves the
removal of 25–30% of lung tissue from both the left
and the right sides. Benefits associated with LVRS
are improved lung function (reduced lung volume
and increased FEV1) and exercise (including the
distance walked in 6min).70 Although carefully
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remain concerning the magnitude and duration of
positive outcome.
The National Emphysema Treatment Trial
(NETT)
The NETT was a multicentre, randomised, large-
scale clinical trial (N ¼ 1218) to evaluate the
effects of LVRS.71 Eligible patients (FEV1o45%
predicted and bilateral emphysema) underwent a
period of medical therapy plus pulmonary rehabi-
litation. After this period, patients were rando-
mised to receive either LVRS (n ¼ 608) or continue
medical therapy (n ¼ 610), with a mean follow-up
time of 29 months. The two primary outcomes
measured were survival and maximum exercise
capacity 2 years after randomisation. Of note was
the early identification of a subgroup of patients
who suffered a high 30-day mortality rate and
showed little benefit after LVRS. These patients
exhibited an FEV1p20% of predicted and either a
homogenous distribution of emphysema or a carbon
monoxide diffusion capacity o20% of predicted.72
NETT results
Overall results from the NETT at 2-years post-
randomisation indicate that LVRS improves exerciseFigure 6 Algorithm for lung-volume-reduction surgery (LVR
Treatment Trial results and independent outcome predictors.7
lower exercise performance had substantially improved out
upper lobe emphysema and higher levels of exercise performcapacity, but does not improve survival compared
with medical therapy. Patients in the LVRS group
also reported improved health status and less
dyspnoea compared with the medical group. Sub-
group analyses showed that patients with upper-
lobe predominant emphysema and low exercise
capacity had improved survival with LVRS, com-
pared with medical therapy; those patients with
mainly non-upper-lobe emphysema and high ex-
ercise capacity showed reduced survival.71 From
these results, two key outcome predictors can be
identified: distribution of emphysema and exercise
capacity following pulmonary rehabilitation. Com-
bined with the factors placing patients at high risk
for LVRS, these predictors allow more targeted
patient selection than was previously possible
(Fig. 6).71Future directions for LVRS research
Key questions remaining concern the role of pre-
operative pulmonary rehabilitation, the mechan-
isms by which LVRS improves lung function and
survival, and the impact of different surgical
techniques on LVRS outcomes. The identification
of long-term predictors of LVRS outcomes would be
a welcome development, while investigating uni-
lateral or repeated LVRS, as well as non-invasiveS) patient selection based on the National Emphysema
1 Patients with predominately upper lobe emphysema and
comes from LVRS, while those with predominately non-
ance had poorer outcomes from this procedure.
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successful in the future.Conclusions
Much recent progress has been made in the
management of COPD, but there are still many
outstanding questions to be resolved. There is an
impetus to evaluate combination therapies, novel
drugs such as PDE4 and LTB4 inhibitors, LTOT and
LVRS and learn whether they will have a role in
shaping future developments in patient-specific
therapy. It is hoped that this momentum will be
maintained and that, in years to come, COPD
management will combine pharmacological and
non-pharmacological therapies to drive and refine
treatment algorithms for the individual patient
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